Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofersen - Biogen/Ionis Pharmaceuticals

Drug Profile

Tofersen - Biogen/Ionis Pharmaceuticals

Alternative Names: 99mTc-MAG3-BIIB067; BIIB 067; ISIS 333611; ISIS-SOD1Rx; SODr/h333611

Latest Information Update: 15 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center for Neurologic Study; Isis Pharmaceuticals; Ludwig Institute for Cancer Research
  • Developer Biogen; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis

Most Recent Events

  • 05 Mar 2019 Phase-III clinical trials in Amyotrophic lateral sclerosis in Germany, United Kingdom, France, Italy, Sweden, USA, Canada, Germany, United Kingdom, France, Italy, Sweden, USA, Canada, Belgium (Intrathecal) (NCT02623699)
  • 20 Dec 2018 Phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in USA (Intrathecal) (NCT03764488)
  • 06 Dec 2018 Interim efficacy data from a (phase I/II trial in Amyotrophic lateral sclerosis released by Biogen and Ionis (9256321)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top